{"id":"W2915372679","doi":"10.1016/j.bbmt.2019.02.014","title":"Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation","year":2019,"lang":"en","type":"review","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; University of Ottawa; Ottawa Hospital","funders":"National Institute of Allergy and Infectious Diseases; Pharmacyclics; Allergan; Mylan; National Institutes of Health; Genentech; Multiple Sclerosis Society; Biogen; Pfizer; Incyte; Bayer HealthCare; Acorda Therapeutics; Atara Biotherapeutics; Gilead Sciences; Sanofi; National Institute for Health and Care Research; Teva Pharmaceutical Industries; EMD Serono; Celgene; Novartis; Alexion Pharmaceuticals; Roche; Genzyme; Amgen; Chugai Pharmaceutical; MedDay Pharmaceuticals; GlaxoSmithKline","keywords":"Medicine; Transplantation; Clinical trial; Multiple sclerosis; Hematopoietic stem cell transplantation; Disease; Surgery; Oncology; Intensive care medicine; Internal medicine; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004186758,0.0005971738,0.001811067,0.0001556667,0.0003309912,0.00003358817,0.0001196483,0.0003657724,0.000005141233],"category_scores_gemma":[0.00002590395,0.0004218409,0.0006664819,0.0001452566,0.0004315333,0.0001242401,0.000009034836,0.0001927919,0.000001112782],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006505555,"about_ca_system_score_gemma":0.0002035691,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003452737,"about_ca_topic_score_gemma":0.000188788,"domain_scores_codex":[0.9972401,0.0002899155,0.0009769248,0.000814246,0.0002116352,0.0004672069],"domain_scores_gemma":[0.9961075,0.002595933,0.0007787962,0.0002561779,0.0001447925,0.0001168325],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.004520344,0.001267417,0.002849346,0.1232005,0.006358446,0.00001711476,0.008214235,0.000004684912,0.2603995,0.00005699447,0.0001443428,0.592967],"study_design_scores_gemma":[0.1711862,0.04895532,0.04500465,0.1095767,0.4419832,0.001607044,0.005941965,0.001015483,0.09649845,0.0005989428,0.07090759,0.006724454],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.1836697,0.7934124,0.004200133,0.0002953203,0.0001915031,0.00700492,0.01113857,0.00007422956,0.00001324617],"genre_scores_gemma":[0.1341291,0.8495362,0.004263709,0.00006127832,0.0001161248,0.0009939149,0.01081448,0.00006183539,0.00002332201],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.5862426,"threshold_uncertainty_score":0.9998233,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07587259970366206,"score_gpt":0.3324805216397326,"score_spread":0.2566079219360706,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}